Correlation of molecular subtypes with survival in AVAglio (bevacizumab [Bv] and radiotherapy [RT] and temozolomide [T] for newly diagnosed glioblastoma [GB])

被引：6
|
作者：
Phillips, Heidi
Sandmann, Thomas
Li, Congfen
Cloughesy, Timothy Francis
Chlnot, Olivier L.
Wick, Wolfgang
Nishikawa, Ryo
Mason, Warren P.
Henriksson, Roger
Saran, Frank
Lai, Albert
Moore, Nicola
Hegde, Priti S.
Abrey, Lauren E.
Bourgon, Richard
Garcia, Josep
Bais, Carlos
机构：
[1] Genentech Inc, San Francisco, CA 94080 USA
[2] Univ Calif Los Angeles, Los Angeles, CA USA
[3] Univ Aix Marseille, CHU Timone, AP HM, Serv Neurooncol, Marseille, France
[4] Heidelberg Univ, Neurooncol, Med Ctr, Heidelberg, Germany
[5] Saitama Med Univ, Saitama, Japan
[6] Princess Margaret Canc Ctr, Toronto, ON, Canada
[7] Reg Canc Ctr Stockholm Gotland, Stockholm, Sweden
[8] Royal Marsden NHS Fdn Trust, Surrey, England
[9] UCLA Neurooncol Program, Los Angeles, CA USA
[10] F Hoffmann La Roche, Basel, Switzerland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.2001
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2001
引用
收藏
页数：1
相关论文
共 50 条
  • [21] NEWLY DIAGNOSED GLIOBLASTOMA TREATED WITH GLIADEL® FOLLOWED BY RADIATION THERAPY (RT), TEMOZOLOMIDE AND BEVACIZUMAB, AND POST-RT BEVACIZUMAB AND TEMOZOLOMIDE: A PHASE II STUDY
    Desjardins, Annick
    Peters, Katherine B.
    Herndon, James E., II
    Bailey, Leigh Ann
    Alderson, Lloyd M.
    Ranjan, Tulika
    Sampson, John H.
    Friedman, Allan H.
    Bigner, Darell D.
    Friedman, Henry S.
    Vredenburgh, James J.
    [J]. NEURO-ONCOLOGY, 2012, 14 : 104 - 104
  • [22] Radiologic progression types are treatment specific: An exploratory analysis of a phase 3 study of bevacizumab plus radiotherapy plus temozolomide for patients with newly diagnosed glioblastoma (AVAglio).
    Nowosielski, Martha
    Chinott, Olivier L.
    Radbrucht, Alexander
    Stockhammer, Guenther
    Garcia, Josep
    Revil, Cedric
    Nishikawa, Ryo
    Mason, Warren P.
    Henriksson, Roger
    Saran, Frank
    Bendszus, Martin
    Abrey, Lauren E.
    Cloughesy, Timothy Francis
    Wick, Wolfgang
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [23] PHASE II STUDY OF BEVACIZUMAB, TEMOZOLOMIDE, AND HYPOFRACTIONATED STEREOTACTIC RADIOTHERAPY (HFSRT) FOR NEWLY DIAGNOSED GLIOBLASTOMA
    Omuro, Antonio
    Beal, Kathryn
    Correa, Denise
    Chan, Timothy
    DeAngelis, Lisa
    Gavrilovic, Igor
    Nolan, Craig
    Hormigo, Adilia
    Lassman, Andrew B.
    Kaley, Thomas
    Mellinghoff, Ingo
    Grommes, Christian
    Panageas, Kathryn
    Reiner, Ann
    Barradas, Renata
    Abrey, Lauren
    Gutin, Philip
    [J]. NEURO-ONCOLOGY, 2011, 13 : 59 - 60
  • [24] FEASIBILITY OF COMBINED TREATMENT WITH BEVACIZUMAB, RADIOTHERAPY, AND TEMOZOLOMIDE IN RESECTABLE AND UNRESECTABLE NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME
    van Linde, Myra E.
    Verhoeff, Joost J. C.
    Stalpers, Lukas J. A.
    Reijneveld, Jaap C.
    Richel, Dirk J.
    Van Furth, Wouter Ralph
    [J]. NEURO-ONCOLOGY, 2009, 11 (05) : 628 - 628
  • [25] Tumor response based on adapted Macdonald criteria and assessment of pseudoprogression (PsPD) in the phase III AV Aglio trial of bevacizumab (Bv) plus temozolomide (T) plus radiotherapy (RT) in newly diagnosed glioblastoma (GBM)
    Wick, Wolfgang
    Cloughesy, Timothy Francis
    Nishikawa, Ryo
    Mason, Warren
    Saran, Frank
    Henriksson, Roger
    Hilton, Magalie
    Kerloeguen, Yannick
    Chinot, Oliver L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [26] Safety and efficacy of the addition of bevacizumab (BV) to temozolomide (TMZ) and radiation therapy (RT) followed by BV, TMZ, and irinotecan (CPT-11) for newly diagnosed glioblastoma multiforme (GBM)
    Vredenburgh, J. J.
    Desjardins, A.
    Reardon, D. A.
    Peters, K.
    Herndon, J. E., II
    Kirkpatrick, J.
    Gururangan, S.
    Bailey, L.
    Friedman, A. H.
    Friedman, H. S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [27] Bevacizumab in combination with radiotherapy plus concomitant and adjuvant temozolomide for newly diagnosed glioblastoma: Update progression-free survival, overall survival, and toxicity
    Gruber, M. L.
    Raza, S.
    Gruber, D.
    Narayana, A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [28] Radiotherapy, temozolomide, and bevacizumab followed by irinotecan, temozolomide and bevacizumab in newly diagnosed glioblastoma multiforme: Preliminary results front an ongoing phase II trial
    Kirkpatrick, J. P.
    Desjardins, A.
    Reardon, D. A.
    Vredenburgh, J. J.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 72 (01): : S209 - S209
  • [29] HEALTH-RELATED QUALITY OF LIFE (HRQOL) ANALYSES IN THE AVAGLIO STUDY, A RANDOMIZED, PLACEBO-CONTROLLED PHASE III TRIAL OF BEVACIZUMAB, TEMOZOLOMIDE AND RADIOTHERAPY IN NEWLY DIAGNOSED GLIOBLASTOMA
    Taphoorn, Martin J. B.
    Henriksson, Roger
    Bottomley, Andrew
    Cloughesy, Timothy
    Wick, Wolfgang
    Mason, Warren
    Saran, Frank
    Nishikawa, Ryo
    Ravelo, Arliene
    Hilton, Magalie
    Chinot, Olivier L.
    [J]. NEURO-ONCOLOGY, 2013, 15 : 232 - 232
  • [30] Pseudoprogression (PsPr) after concurrent radiotherapy (RT) and temozolomide (TMZ) for newly diagnosed glioblastoma multiforme (GBM)
    Clarke, J. L.
    Abrey, L. E.
    Karimi, S.
    Lassman, A. B.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345